NASDAQ:ACET Adicet Bio (ACET) Stock Forecast, Price & News $1.43 +0.03 (+2.14%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$1.37▼$1.5550-Day Range$1.40▼$3.2252-Week Range$1.37▼$21.87Volume193,727 shsAverage Volume634,223 shsMarket Capitalization$61.59 millionP/E RatioN/ADividend YieldN/APrice Target$17.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Adicet Bio MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside1,123.8% Upside$17.50 Price TargetShort InterestBearish8.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$1.84 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.93) to ($2.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector316th out of 964 stocksPharmaceutical Preparations Industry129th out of 445 stocks 3.3 Analyst's Opinion Consensus RatingAdicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.50, Adicet Bio has a forecasted upside of 1,123.8% from its current price of $1.43.Amount of Analyst CoverageAdicet Bio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.95% of the float of Adicet Bio has been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adicet Bio has recently increased by 9.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACET. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Adicet Bio this week, compared to 2 articles on an average week.Search Interest6 people have searched for ACET on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows2 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,840,750.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders29.50% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.29% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Adicet Bio are expected to grow in the coming year, from ($2.93) to ($2.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adicet Bio (NASDAQ:ACET) StockAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.Read More ACET Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACET Stock News HeadlinesSeptember 6, 2023 | msn.comTruist Securities Reiterates Adicet Bio (ACET) Buy RecommendationAugust 12, 2023 | finance.yahoo.comWill Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?September 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 11, 2023 | msn.comBTIG Maintains Adicet Bio (ACET) Buy RecommendationAugust 9, 2023 | finance.yahoo.comAdicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue EstimatesAugust 9, 2023 | markets.businessinsider.comAdicet Bio, Inc Q2 Loss increases, misses estimatesAugust 9, 2023 | finance.yahoo.comAdicet Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 3, 2023 | finance.yahoo.comAdicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth ConferenceSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJuly 12, 2023 | benzinga.comAdicet Bio Director Awarded $236K Worth of Stock OptionsJuly 11, 2023 | finance.yahoo.comAdicet Announces Appointment of Katie Peng to the Board of DirectorsJuly 6, 2023 | msn.comAdicet Bio (ACET) Price Target Decreased by 12.90% to 24.48June 30, 2023 | benzinga.comMassive Insider Trade At Adicet BioJune 30, 2023 | benzinga.comDirector of Adicet Bio Purchased $1.83M In StockJune 27, 2023 | msn.comJMP downgrades Adicet to market perform, citing study delayJune 27, 2023 | msn.comAdicet Bio Stock Craters 54% after JMP DowngradeJune 27, 2023 | markets.businessinsider.comAnalyst Downgrades Adicet Citing Uncertainty, Awaits Long-Term Data On DurabilityJune 27, 2023 | markets.businessinsider.com6 Analysts Have This to Say About Adicet BioJune 27, 2023 | msn.comMoonLake Immunotherapeutics, Applied Digital And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionJune 27, 2023 | markets.businessinsider.comAdicet Bio (ACET) was downgraded to a Hold Rating at JMP SecuritiesJune 27, 2023 | benzinga.comAdicet Bio Stock Is Falling Premarket - Here's WhyJune 13, 2023 | markets.businessinsider.comJonesTrading Reaffirms Their Buy Rating on Adicet Bio (ACET)June 2, 2023 | msn.comJP Morgan Downgrades Adicet Bio (ACET)June 1, 2023 | finance.yahoo.comAdicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare ConferenceMay 18, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Adicet Bio (ACET)May 18, 2023 | msn.comAdicet Bio's Cancer Candidate Shows Anti-Tumor Activity In Preclinical StudyMay 18, 2023 | finance.yahoo.comAdicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual MeetingSee More Headlines Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ACET Company Calendar Last Earnings8/09/2023Today9/26/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryTrading Companies & Distributors SectorMedical Current SymbolNASDAQ:ACET CUSIP00444610 CIK2034 Webwww.aceto.com Phone(650) 503-9095FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.50 High Stock Price Forecast$27.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+1,074.5%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,790,000.00 Net MarginsN/A Pretax Margin-279.27% Return on Equity-41.30% Return on Assets-36.34% Debt Debt-to-Equity RatioN/A Current Ratio11.08 Quick Ratio11.08 Sales & Book Value Annual Sales$24.99 million Price / Sales2.57 Cash FlowN/A Price / Cash FlowN/A Book Value$6.82 per share Price / Book0.22Miscellaneous Outstanding Shares43,070,000Free Float30,362,000Market Cap$64.17 million OptionableOptionable Beta1.96 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Chen Schor BA (Age 51)CPA, CPA, M.B.A., MBA, CEO, Pres & Director Comp: $899.58kDr. Aya Jakobovits Ph.D. (Age 68)Founder & Independent Director Comp: $40kDr. Blake Aftab Ph.D. (Age 42)Sr. VP & Chief Scientific Officer Comp: $675.04kDr. Francesco Galimi M.D. (Age 55)Ph.D., Chief Medical Officer & Sr. VP Comp: $680.37kMr. Brian Nicholas Harvey (Age 62)Chief Financial Officer Dr. Donald Healey Ph.D. (Age 61)Chief Technology Officer Ms. Amy LockeHead of HRDr. Nancy L. Boman M.D.Ph.D., Sr. VP & Chief Regulatory OfficerMore ExecutivesKey CompetitorsProPhase LabsNASDAQ:PRPHPyxis OncologyNASDAQ:PYXSVeruNASDAQ:VERUZynerba PharmaceuticalsNASDAQ:ZYNEViveon Health AcquisitionNYSE:VHAQView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemSold 18,061 shares on 8/21/2023Ownership: 0.023%Nuveen Asset Management LLCBought 69,071 shares on 8/16/2023Ownership: 0.380%Alliancebernstein L.P.Bought 9,640 shares on 8/15/2023Ownership: 0.094%Citadel Advisors LLCSold 2,200 shares on 8/15/2023Ownership: 0.000%Wells Fargo & Company MNBought 6,186 shares on 8/15/2023Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions ACET Stock - Frequently Asked Questions Should I buy or sell Adicet Bio stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACET shares. View ACET analyst ratings or view top-rated stocks. What is Adicet Bio's stock price forecast for 2023? 7 brokerages have issued twelve-month target prices for Adicet Bio's shares. Their ACET share price forecasts range from $6.00 to $27.00. On average, they anticipate the company's share price to reach $17.50 in the next year. This suggests a possible upside of 1,074.5% from the stock's current price. View analysts price targets for ACET or view top-rated stocks among Wall Street analysts. How have ACET shares performed in 2023? Adicet Bio's stock was trading at $8.94 on January 1st, 2023. Since then, ACET shares have decreased by 83.3% and is now trading at $1.49. View the best growth stocks for 2023 here. When is Adicet Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ACET earnings forecast. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.07. What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE). What is Adicet Bio's stock symbol? Adicet Bio trades on the NASDAQ under the ticker symbol "ACET." Who are Adicet Bio's major shareholders? Adicet Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cowen AND Company LLC (6.60%), BlackRock Inc. (5.56%), Candriam S.C.A. (1.67%), Geode Capital Management LLC (1.47%), Decheng Capital Management III Cayman LLC (1.18%) and Dimensional Fund Advisors LP (0.77%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Jay P Elliott and Steve Dubin. View institutional ownership trends. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adicet Bio's stock price today? One share of ACET stock can currently be purchased for approximately $1.49. How much money does Adicet Bio make? Adicet Bio (NASDAQ:ACET) has a market capitalization of $64.17 million and generates $24.99 million in revenue each year. The company earns $-69,790,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. How many employees does Adicet Bio have? The company employs 132 workers across the globe. How can I contact Adicet Bio? Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The official website for the company is www.aceto.com. The company can be reached via phone at (650) 503-9095 or via email at jburfening@lhai.com. This page (NASDAQ:ACET) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.